Developer docs
API playgroundTry for free, no card

Search company profiles

MalarVx

Full company profile

uuid000eeiy

Namestring
MalarVx
Legal namestring
MalarVx, Inc.
Websiteurl
malarvx.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

MalarVx, Inc. is a privately-held, clinical-stage biopharmaceutical company founded in 2012 and headquartered in Seattle, Washington. The company develops malaria vaccines targeting both Plasmodium falciparum and Plasmodium vivax using two integrated technology platforms: (1) a self-amplifying replicon RNA (repRNA) delivered via HDT Bio's LION lipid nanocarrier, licensed in June 2025, and (2) whole-organism attenuated parasites (radiation-attenuated sporozoites and genetically-attenuated parasites) produced through a proprietary in vitro culture system that grows sporozoites without mosquitoes using a 3D AlgiMatrix scaffold. Its lead approach is a heterologous 'prime-and-trap' regimen combining a repRNA-LION prime with a radiation-attenuated sporozoite trap, designed for same-day administration, reduced cold-chain requirements, and potential multi-species coverage.

The company reports preclinical sterile protection of 80–100%, materially higher than the ~39% efficacy of WHO-approved RTS,S. MalarVx is pre-revenue, funded historically by a single disclosed $110,000 equity round in January 2015 plus ongoing grants from the National Institutes of Health and the U.S. Department of Defense, and operates with a lean team of approximately 6–10 people. Its commercial model contemplates future one-time product sales (and/or licensing) to endemic-region governments and global health organizations such as WHO, Gavi, and UNICEF, targeting children under five and pregnant women in resource-limited malaria-endemic settings where roughly 597,000 deaths and 263 million cases were reported in 2023.

Short descriptiontext

MalarVx is a Seattle-based clinical-stage biopharmaceutical company developing malaria vaccines that combine self-amplifying RNA, lipid nanocarriers, and in vitro cultured attenuated parasites to prevent P. falciparum and P. vivax infection in endemic regions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
malaria vaccines, RNA vaccine technology, whole parasite vaccines, prime-and-trap vaccination, in vitro sporozoite production
Industry3 codes
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAF
Pandemic Preparedness & Rapid-Response Vaccines
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Malaria Vaccines
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Vaccine Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage company focused on developing malaria vaccines. Revenue model will be based on vaccine product sales once regulatory approval is obtained. Target markets include endemic region governments, global health organizations, and public health initiatives.

malarvx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

MalarVx develops clinical-stage malaria vaccine candidates built on a self-amplifying replicon RNA (repRNA) subunit prime delivered via HDT Bio's LION lipid nanocarrier, combined with radiation- or genetically-attenuated whole Plasmodium falciparum sporozoites as a boost. The pipeline targets both P. falciparum and P. vivax malaria and is supported by a proprietary in vitro sporozoite production platform that eliminates the need for mosquito-based manufacturing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 80-100% sterile protection in preclinical studies
+1 more record
Product overview1 text field

MalarVx is developing a pipeline of malaria vaccine candidates targeting both Plasmodium falciparum and Plasmodium vivax parasites. The company's portfolio includes two technology platforms: (1) repRNA/LION, a self-amplifying RNA vaccine delivered via lipid nanoparticle; and (2) whole organism vaccines using in vitro cultured sporozoites, including radiation-attenuated sporozoites (RAS) and genetically-attenuated parasites (GAP). The Prime-and-Trap approach combines these platforms using a repRNA subunit prime followed by attenuated sporozoite boost to maximize protective immunity.

Product and service3 records
1Prime-and-Trap Malaria Vaccine
CategoryMalaria vaccine (prime-boost)
Description

A heterologous prime-boost malaria vaccination strategy that combines a repRNA-based CSP subunit vaccine (delivered via LION nanocarrier) as the prime with radiation-attenuated sporozoites (RAS) as the trap/boost, designed to engage both humoral and cellular immunity against Plasmodium falciparum for endemic-region use.

2repRNA/LION Malaria Vaccine
CategoryRNA subunit vaccine
Description

A self-amplifying replicon RNA (repRNA) vaccine candidate delivered via HDT Bio's LION (Lipid InOrganic Nanoparticle) nanocarrier system, designed to induce immune protection against Plasmodium falciparum with enhanced thermal stability (4°C up to one year; room temperature for several days).

3In Vitro Cultured Sporozoites (RAS / GAP whole-parasite vaccine)
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-06-04
Description

MalarVx licensed HDT Bio's proprietary self-amplifying replicon RNA (repRNA) and lipid nanoparticle (LION) technologies for use in malaria vaccines. HDT Bio is a Seattle-based clinical-stage biopharmaceutical company specializing in advanced RNA vaccine technologies. The agreement provides MalarVx additional support from HDT to develop and commercialize malaria vaccines. HDT Bio's LION platform has demonstrated ability to rapidly generate potent, durable immune responses with favorable safety profile. This expands the long-standing relationship between the parties.

2Oregon Health Sciences University (OHSU)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Dr. Brandon Wilder's malaria research program at OHSU (formerly at NAMRU-6 in Lima, Peru). Dr. Wilder serves on MalarVx's Advisory Board.

malarvx.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Dr. Sean Murphy and Dr. Melanie Sears at University of Washington, Seattle WA, for cellular immunity analysis.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Historical collaboration with Bloodworks NW, Seattle WA, for blood and blood products used for culturing Plasmodium parasites.

5Walter Reed Army Institute of Research (WRAIR)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Historical collaboration with WRAIR in Maryland DC for malaria research.

malarvx.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

HDT Bio is the licensor of the repRNA and LION nanoparticle technology underpinning MalarVx's vaccine; it is also an independent RNA vaccine developer with overlapping platform technology and potential pipeline overlap.

TypeDirect peer
Description

Sanaria develops radiation-attenuated sporozoite (PfSPZ) malaria vaccines—the same whole-organism approach that anchors MalarVx's prime-and-trap regimen. They compete directly for global health procurement and clinical-trial partnerships.

TypeDirect peer
Description

GSK developed RTS,S/Mosquirix, the first WHO-recommended malaria vaccine, targeting the same P. falciparum market and global health customer base that MalarVx ultimately serves.

TypeDirect peer
Description

Bharat Biotech co-developed R21/Matrix-M with the Jenner Institute; WHO-recommended in 2023, it is rapidly scaling and competing directly with MalarVx's target market of endemic-country immunization programs.

TypeEmerging player
Description

BioNTech is developing an mRNA-based malaria vaccine candidate (BNT165) using the same RNA vaccine modality that underpins MalarVx's repRNA prime; it represents a much larger, well-capitalized competitor pursuing the same next-generation malaria vaccine opportunity.

TypeEmerging player
Description

Moderna's mRNA platform includes a malaria vaccine program (mRNA-6930) that competes in the same nucleic-acid vaccine category as MalarVx's repRNA-LION product.

TypeOthers
Description

PATH's MVI is a global health product development partnership that funds and supports advanced malaria vaccine candidates; it is a likely funding, partnership, and procurement intermediary for MalarVx.

8Jenner Institute (University of Oxford)
TypeEmerging player
Description

The Jenner Institute co-developed R21/Matrix-M and remains one of the leading malaria vaccinology groups, competing for talent, grant funding, and clinical-trial sites that MalarVx also needs.

TypeBroad incumbent
Description

Novavax is a larger recombinant protein vaccine platform company whose Matrix-M adjuvant is used in R21; while not focused on malaria, its adjuvant franchise positions it as an enabling technology supplier in the same disease area.

10Walter Reed Army Institute of Research (WRAIR)
TypeOthers
Description

WRAIR is a historical MalarVx collaborator and an independent developer of malaria vaccines (including whole sporozoite approaches); it represents both a partnership opportunity and an institutional competitor for U.S. DoD malaria funding.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MalarVx

Malaria Vaccinesmalarvx.com

MalarVx is a Seattle-based clinical-stage biopharmaceutical company developing malaria vaccines that combine self-amplifying RNA, lipid nanocarriers, and in vitro cultured attenuated parasites to prevent P. falciparum and P. vivax infection in endemic regions.

What MalarVx does

MalarVx, Inc. is a privately-held, clinical-stage biopharmaceutical company founded in 2012 and headquartered in Seattle, Washington. The company develops malaria vaccines targeting both Plasmodium falciparum and Plasmodium vivax using two integrated technology platforms: (1) a self-amplifying replicon RNA (repRNA) delivered via HDT Bio's LION lipid nanocarrier, licensed in June 2025, and (2) whole-organism attenuated parasites (radiation-attenuated sporozoites and genetically-attenuated parasites) produced through a proprietary in vitro culture system that grows sporozoites without mosquitoes using a 3D AlgiMatrix scaffold. Its lead approach is a heterologous 'prime-and-trap' regimen combining a repRNA-LION prime with a radiation-attenuated sporozoite trap, designed for same-day administration, reduced cold-chain requirements, and potential multi-species coverage.

The company reports preclinical sterile protection of 80–100%, materially higher than the ~39% efficacy of WHO-approved RTS,S. MalarVx is pre-revenue, funded historically by a single disclosed $110,000 equity round in January 2015 plus ongoing grants from the National Institutes of Health and the U.S. Department of Defense, and operates with a lean team of approximately 6–10 people. Its commercial model contemplates future one-time product sales (and/or licensing) to endemic-region governments and global health organizations such as WHO, Gavi, and UNICEF, targeting children under five and pregnant women in resource-limited malaria-endemic settings where roughly 597,000 deaths and 263 million cases were reported in 2023.

MalarVx firmographics

Firmographics
Name
MalarVx
Legal name
MalarVx, Inc.
Website
https://malarvx.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
1–10 employees
Short description
MalarVx is a Seattle-based clinical-stage biopharmaceutical company developing malaria vaccines that combine self-amplifying RNA, lipid nanocarriers, and in vitro cultured attenuated parasites to prevent P. falciparum and P. vivax infection in endemic regions.
Ownership category
akta.pro rank

MalarVx industry classification

Industry
Product category
Malaria Vaccines
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAC
Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAF
Pandemic Preparedness & Rapid-Response Vaccines

Keywords

  • Malaria vaccines
  • RNA vaccine technology
  • Whole parasite vaccines
  • Prime-and-trap vaccination
  • In vitro sporozoite production

Where MalarVx is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices1 record

Markets served

MalarVx business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Vaccine Development and Commercialization: Pre-revenue clinical-stage company focused on developing malaria vaccines. Revenue model will be based on vaccine product sales once regulatory approval is obtained. Target markets include endemic region governments, global health organizations, and public health initiatives.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

MalarVx product offering

Product offering

Core offering

MalarVx develops clinical-stage malaria vaccine candidates built on a self-amplifying replicon RNA (repRNA) subunit prime delivered via HDT Bio's LION lipid nanocarrier, combined with radiation- or genetically-attenuated whole Plasmodium falciparum sporozoites as a boost. The pipeline targets both P. falciparum and P. vivax malaria and is supported by a proprietary in vitro sporozoite production platform that eliminates the need for mosquito-based manufacturing.

Product overview

MalarVx is developing a pipeline of malaria vaccine candidates targeting both Plasmodium falciparum and Plasmodium vivax parasites. The company's portfolio includes two technology platforms: (1) repRNA/LION, a self-amplifying RNA vaccine delivered via lipid nanoparticle; and (2) whole organism vaccines using in vitro cultured sporozoites, including radiation-attenuated sporozoites (RAS) and genetically-attenuated parasites (GAP). The Prime-and-Trap approach combines these platforms using a repRNA subunit prime followed by attenuated sporozoite boost to maximize protective immunity.

Differentiator

Problem solved

Functional benefit

Products and services

  • Prime-and-Trap Malaria Vaccine A heterologous prime-boost malaria vaccination strategy that combines a repRNA-based CSP subunit vaccine (delivered via LION nanocarrier) as the prime with radiation-attenuated sporozoites (RAS) as the trap/boost, designed to engage both humoral and cellular immunity against Plasmodium falciparum for endemic-region use.
  • repRNA/LION Malaria Vaccine A self-amplifying replicon RNA (repRNA) vaccine candidate delivered via HDT Bio's LION (Lipid InOrganic Nanoparticle) nanocarrier system, designed to induce immune protection against Plasmodium falciparum with enhanced thermal stability (4°C up to one year; room temperature for several days).
  • In Vitro Cultured Sporozoites (RAS / GAP whole-parasite vaccine)

Quantifiable outcome

  • 80-100% sterile protection in preclinical studies
  • +1 more outcomes

Companies that use MalarVx

Customer profile

Segments2 records

Ideal customer profiles1 record

MalarVx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

MalarVx partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • HDT BiocoreTechnology or Integration · 4 June 2025MalarVx licensed HDT Bio's proprietary self-amplifying replicon RNA (repRNA) and lipid nanoparticle (LION) technologies for use in malaria vaccines. HDT Bio is a Seattle-based clinical-stage biopharmaceutical company specializing in advanced RNA vaccine technologies. The agreement provides MalarVx additional support from HDT to develop and commercialize malaria vaccines. HDT Bio's LION platform has demonstrated ability to rapidly generate potent, durable immune responses with favorable safety profile. This expands the long-standing relationship between the parties.
  • Oregon Health Sciences University (OHSU)coreStrategic or Co-development PartnerCollaboration with Dr. Brandon Wilder's malaria research program at OHSU (formerly at NAMRU-6 in Lima, Peru). Dr. Wilder serves on MalarVx's Advisory Board.
  • University of WashingtoncoreStrategic or Co-development PartnerCollaboration with Dr. Sean Murphy and Dr. Melanie Sears at University of Washington, Seattle WA, for cellular immunity analysis.
  • Bloodworks NWminorStrategic or Co-development PartnerHistorical collaboration with Bloodworks NW, Seattle WA, for blood and blood products used for culturing Plasmodium parasites.
  • Walter Reed Army Institute of Research (WRAIR)minorStrategic or Co-development PartnerHistorical collaboration with WRAIR in Maryland DC for malaria research.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

MalarVx competitors and assessment

Company assessment

Others

  • HDT Bio: HDT Bio is the licensor of the repRNA and LION nanoparticle technology underpinning MalarVx's vaccine; it is also an independent RNA vaccine developer with overlapping platform technology and potential pipeline overlap.
  • PATH Malaria Vaccine Initiative: PATH's MVI is a global health product development partnership that funds and supports advanced malaria vaccine candidates; it is a likely funding, partnership, and procurement intermediary for MalarVx.
  • Walter Reed Army Institute of Research (WRAIR): WRAIR is a historical MalarVx collaborator and an independent developer of malaria vaccines (including whole sporozoite approaches); it represents both a partnership opportunity and an institutional competitor for U.S. DoD malaria funding.

Direct peers

  • Sanaria Inc. Sanaria develops radiation-attenuated sporozoite (PfSPZ) malaria vaccines—the same whole-organism approach that anchors MalarVx's prime-and-trap regimen. They compete directly for global health procurement and clinical-trial partnerships.
  • GSK (RTS,S/Mosquirix): GSK developed RTS,S/Mosquirix, the first WHO-recommended malaria vaccine, targeting the same P. falciparum market and global health customer base that MalarVx ultimately serves.
  • Bharat Biotech (R21/Matrix-M): Bharat Biotech co-developed R21/Matrix-M with the Jenner Institute; WHO-recommended in 2023, it is rapidly scaling and competing directly with MalarVx's target market of endemic-country immunization programs.

Emerging players

  • BioNTech: BioNTech is developing an mRNA-based malaria vaccine candidate (BNT165) using the same RNA vaccine modality that underpins MalarVx's repRNA prime; it represents a much larger, well-capitalized competitor pursuing the same next-generation malaria vaccine opportunity.
  • Moderna: Moderna's mRNA platform includes a malaria vaccine program (mRNA-6930) that competes in the same nucleic-acid vaccine category as MalarVx's repRNA-LION product.
  • Jenner Institute (University of Oxford): The Jenner Institute co-developed R21/Matrix-M and remains one of the leading malaria vaccinology groups, competing for talent, grant funding, and clinical-trial sites that MalarVx also needs.

Broad incumbents

  • Novavax: Novavax is a larger recombinant protein vaccine platform company whose Matrix-M adjuvant is used in R21; while not focused on malaria, its adjuvant franchise positions it as an enabling technology supplier in the same disease area.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

MalarVx social profiles

Digital presence

MalarVx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MalarVx leadership team

Management profile

Number of profiles

Profiles7 records

MalarVx funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MalarVx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MalarVx

What does MalarVx do?

MalarVx develops clinical-stage malaria vaccine candidates built on a self-amplifying replicon RNA (repRNA) subunit prime delivered via HDT Bio's LION lipid nanocarrier, combined with radiation- or genetically-attenuated whole Plasmodium falciparum sporozoites as a boost. The pipeline targets both P. falciparum and P. vivax malaria and is supported by a proprietary in vitro sporozoite production platform that eliminates the need for mosquito-based manufacturing.

Is MalarVx a public or private company?

MalarVx is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was MalarVx founded?

MalarVx was founded in 2012. It employs 1 to 10 people.

Where is MalarVx based?

MalarVx is headquartered in Seattle, United States, in the North America region.

How does MalarVx make money?

One revenue line is on record: vaccine Development and Commercialization.

Who are MalarVx's main competitors?

Others on record are HDT Bio, PATH Malaria Vaccine Initiative and Walter Reed Army Institute of Research (WRAIR). Direct peers are Sanaria Inc., GSK (RTS,S/Mosquirix) and Bharat Biotech (R21/Matrix-M). Emerging players are BioNTech, Moderna and Jenner Institute (University of Oxford). Novavax is listed as a broad incumbent.

Does MalarVx have an API?

No public API is recorded for MalarVx.

What industry is MalarVx in?

MalarVx's product category is Malaria Vaccines. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAAAEAC, Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals